Pediatric Innovation: FDA Issues Approval For This Medical Device

FDA Advances Pediatric Medical Innovation with Approvable Letter for SeaStar's Selective Cytopheretic Device.

In a landmark decision that signifies progress in pediatric healthcare, the U.S. Food and Drug Administration (FDA) has issued an approvable letter for SeaStar Medical's Selective Cytopheretic Device (SCD) for pediatric patients. This pivotal development is set to transform the lives of countless children suffering from acute kidney injury (AKI), offeri…